Alpha Cognition's ZUNVEYL Shows Strong Traction in Long-Term Care Market with Record Quarterly Revenue

Stonegate Capital Partners has updated its coverage on Alpha Cognition Inc., highlighting the company's fourth quarter 2025 performance that indicates ZUNVEYL is gaining durable traction in the long-term care market. Alpha Cognition reported $2.5 million in net product revenue for the fourth quarter of 2025, bringing total fiscal year 2025 revenue to $10.2 million, which includes $6.8 million from ZUNVEYL sales. The company's financial position remains strong with $66.0 million in cash at the end of FY25, providing runway into 2027 and supporting continued commercialization efforts.

Demand indicators showed significant improvement during the quarter, with bottles dispensed rising 62% quarter-over-quarter to 4,941 units. December alone reached a record 1,859 bottles, demonstrating accelerating adoption. The company reported 729 ordering homes with 82% repeat orders, while 865 prescribers showed 69% repeat writing behavior. These metrics support management's view that ZUNVEYL is moving beyond early trial use and becoming more embedded in facility treatment protocols. The repeat ordering behavior suggests the treatment is establishing itself as a standard component of care in long-term facilities.

Stonegate Capital Partners' analysis indicates that Alpha Cognition's commercialization strategy is gaining momentum, with the company expecting continued sequential sales growth throughout 2026. The strong repeat order rates among both facilities and prescribers suggest that ZUNVEYL is demonstrating clinical value that supports ongoing utilization. The company's financial resources position it to continue scaling its commercialization efforts without immediate need for additional capital. For more detailed information about the coverage update, visit https://www.stonegateinc.com.

The increasing adoption metrics come as the long-term care market continues to evolve its treatment approaches for cognitive conditions. The 62% quarter-over-quarter growth in bottles dispensed represents one of the strongest indicators of market acceptance. With 82% of ordering homes returning for additional supplies and 69% of prescribers writing repeat prescriptions, the data suggests ZUNVEYL is achieving the kind of sustained usage that typically precedes broader market penetration. The company's performance in the fourth quarter of 2025 provides evidence that its therapeutic approach is resonating with both healthcare providers and facilities.